Redeye leaves a comment following OncoZenge’s announcement of an amended agreement with Molteni Farmaceutici, transferring full responsibility for the commercial-scale manufacturing of BupiZenge to the Italian partner. We view this as a strategically positive development that reinforces OncoZenge's asset-light model and de-risks the commercialization pathway.
LÄS MER